Brief: Enlivex Announces Research Collaboration With Yale Cancer Center
22/03/2021 12:08
March 22 (Reuters) - Enlivex Therapeutics Ltd ENLV.TA :
* ENLIVEX ANNOUNCES RESEARCH COLLABORATION WITH YALE CANCER
CENTER
TO ASSESS SYNERGISTIC EFFECT OF ALLOCETRA™ IN COMBINATION WITH
IMMUNE CHECKPOINT INHIBITORS
* ENLIVEX THERAPEUTICS LTD - PLANS TO INITIATE A CONTROLLED,
RANDOMIZED, PHASE IIB STUDY IN SEPSIS DURING Q1 OF 2021
Source text for Eikon: ID:nGNX5wXxYB
Further company coverage: ENLV.TA
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Enlivex
See all newsBrief: Enlivex Ltd Registers Up To 23,333,333 Ordinary Shares For Resale By Selling Shareholder
Brief: Enlivex Announces Second Regulatory Approval For Phase 2B Trial Of Allocetra In Age-Related Primary Moderate-To-Severe Knee Osteoarthritis
Brief: Enlivex Therapeutics Files For Offering Of Up To $299.6 Mln Of Ordinary Shares
Brief: Enlivex Announces Positive 6-Month Topline Data For Patients with Knee Osteoarthritis
Brief: Enlivex Files Patent for Allocetra Use in Osteoarthritis Treatment